Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of AGMB-129 and Midazolam in Healthy Participants
NCT05937386Phase 1Completed
- Sponsor
- Agomab Therapeutics
- Start
- Aug 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ontunisertib in Crohn's disease, sponsored by Agomab Therapeutics. Primary endpoints: Maximum Plasma Concentration (Cmax) for Midazolam at Day 13, Maximum Plasma Concentration (Cmax) for 1-OH-midazolam at Day 13 and 2 more. Started Aug 2023; status: completed.
02
Drugs
ontunisertib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT05937386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05937386.